Inverness acquires 51% of diagnostics maker Diamics
Diamics, a Novato, Calif., maker of cancer diagnostics, raised $6 million by selling a 51 percent stake to Inverness Medical Innovations, a publicly traded diagnostic company.
Diamics is developing an improved system for taking Pap smears used in the early detection of cervical cancer. Inverness will assist in new-product design, manufacturing and distribution.
Next Story: Viroblock pulls in first-round funding
Previous Story: Google earmarks $4.6 billion for wireless bid, backs Ubiquisys
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
